SCHEMBL17405142

SCHEMBL17405142

CCCC(=O)Nc1ccc(-c2ccc(C)cc2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.86
POLB P06746 2/20 0.64
ALDH1A1 P00352 3/20 0.60
HDAC3 O15379 3/20 0.60
HDAC1 Q13547 3/20 0.60
HDAC2 Q92769 3/20 0.60
HDAC10 Q969S8 3/20 0.60
HDAC11 Q96DB2 3/20 0.60
HDAC8 Q9BY41 3/20 0.60
HDAC6 Q9UBN7 3/20 0.60
HPGD P15428 2/20 0.60
HDAC4 P56524 2/20 0.60
HDAC7 Q8WUI4 2/20 0.60
HDAC9 Q9UKV0 2/20 0.60
HDAC5 Q9UQL6 2/20 0.60
MAPT P10636 2/20 0.60
ADORA3 P0DMS8 2/20 0.59
ADORA1 P30542 1/20 0.59
NCOR2 Q9Y618 1/20 0.58
NPC1 O15118 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8361539 0.94 TP53 (0.75) TP53POLBALDH1A1HDAC3HDAC1
SCHEMBL14447210 0.85 MTNR1B (0.66) TP53POLBALDH1A1HDAC3HDAC1
SCHEMBL14578751 0.85 POLB (0.85) TP53POLBALDH1A1HDAC3HDAC1
SCHEMBL28850547 0.84 TP53 (0.83) TP53POLBALDH1A1HDAC3HDAC1
SCHEMBL8813883 0.84 TP53 (0.83) TP53ALDH1A1HDAC3HDAC1HDAC2
SCHEMBL6694936 0.84 HDAC3 (0.72) TP53POLBALDH1A1HDAC3HDAC1
SCHEMBL11186008 0.83 TP53 (0.80) TP53ALDH1A1HDAC3HDAC1HDAC2
SCHEMBL26420478 0.82 HDAC3 (0.75) POLBALDH1A1HDAC3HDAC1HDAC2
Methane SCHEMBL28141646 0.82 HDAC3 (0.70) TP53POLBALDH1A1HDAC3HDAC1
SCHEMBL28778390 0.81 POLB (0.68) TP53POLBALDH1A1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9693997-B2 Antiviral compounds HOFFMANN-LA ROCHE INC. (US) 2017-07-04 US disclosed
US-20160000760-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000760-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS TP53 2824/4885POLB 1035/4885ALDH1A1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.